ChemotherapyFDA-approvedSecond-line
Docetaxel
How it works
Interferes with cell division, preventing cancer cells from growing and dividing.
Cancer types
Efficacy
Docetaxel has been shown to improve overall survival and delay disease progression in patients with advanced prostate cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for HER2 Positive Breast Cancer | Breast Cancer | phase-3 | Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004). | Source → |
| Evaluating Nivolumab and Docetaxel for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Study of a New Medicine for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Insights into Prostate Cancer Treatment Options | Prostate Cancer | meta-analysis | Darolutamide + docetaxel + ADT showed significant benefit over docetaxel + ADT, ADT and standard-nonsteroidal-antiandrogen + ADT in all analyses. | Source → |
| Eugenol Derivatives Enhance Chemotherapy Effectiveness in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| Chemotherapy Combination Affects Lung Cancer Cells in Lab Experiments | Lung Cancer | lab-study | — | Source → |
| Hospitalization Risks Vary for Prostate Cancer Patients on Different Treatments | Prostate Cancer | observational | — | Source → |
| Early Docetaxel and Enzalutamide for Prostate Cancer: New Insights | Prostate Cancer | phase-3 | Among those assigned no enzalutamide, OS was longer with the planned use of early docetaxel (HR 0.90, 95% CI 0.82-0.98), especially in high-volume disease. | Source → |
| METTL14's Role in Lung Cancer Progression and Docetaxel Resistance | Lung Cancer | lab-study | — | Source → |
| Atezolizumab Compared to Docetaxel in Lung Cancer Treatment | Lung Cancer | meta-analysis | Atezolizumab had better efficacy than docetaxel for overall survival (HR: 0.77, 95% CI: 0.73 to 0.81). | Source → |
| New Nanoparticle Delivery System Shows Promise for Breast Cancer Treatment | Breast Cancer | lab-study | The cRGD-HA-CDU@DTX system exhibited a 64.12% tumor growth reduction. | Source → |
| Real-world safety of docetaxel for lung cancer treatment | Lung Cancer | observational | — | Source → |
| GRIM-19's Role in Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.